Skip to main content

MEASuRE: Metreleptin Effectiveness And Safety Registry

Recruiting · NCT02325674

Conditions: Generalised Lipodystrophy, Partial Lipodystrophy

At a glance

Research payments reported, 2025
$64,280
U.S. investigators named
11
Sites paid
11
Planned or actual enrollment
100

About the trial

Sponsor
Chiesi Farmaceutici S.p.A.
Tested
Metreleptin (drug)
Dates
Started 2016-10-11; completion 2031-10-31
Results posted
Not yet

The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.

From ClinicalTrials.gov, last updated 2026-07-16. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Chiesi USA, Inc. reported $64,280 in research payments for this study in 2025 (93 payments).

Products named: Myalept

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.